OBI-833 (Globo H-CRM197)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for OBI-833 (Globo H-CRM197), covering 2022-10-03 to 2022-10-03. Get the full timeline:
Most recent: Clinical Trial Update: Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects [Phase 1]